The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026: What It Means for Providers Compounded "semaglutide" is not FDA approved semaglutide.com